The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 111-125

  Miglio, Gianluca ^a   Rosa, Arianna Carolina ^a   Rattazzi, Lorenza ^a   Grange, Cristina ^b   Collino, Massimo ^a   Camussi, Giovanni ^b   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

cell death; in vitro studies; ischemia reperfusion; podocytes

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; GEMFIBROZIL; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL HYPOXIA; CELL IMMORTALIZATION; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY INJURY; KIDNEY ISCHEMIA; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; REPERFUSION INJURY;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CULTURE MEDIA, SERUM-FREE; ENZYME ACTIVATION; HUMANS; MICROSCOPY, CONFOCAL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PODOCYTES; POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 78650142241     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01032.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158: S1-S254.
2. Andersson M, Nilsson U, Hjalmarsson C, Haraldsson B, Nyström JS, (2007). Mild renal ischemia-reperfusion reduces charge and size selectivity of the glomerular barrier. Am J Physiol Renal Physiol 292: F1802-F1809.
3. Aras MA, Hartnett KA, Aizenman E, (2008). Assessment of cell viability in primary neuronal cultures. Curr Protoc Neurosci 44: 7.18.1-7.18.15.
4. Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, et al. (2006). Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 17: 1624-1632.
5. Berger J, Moller DE, (2002). The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
6. Boulanger H, Mansouri R, Gautier JF, Glotz D, (2006). Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol Dial Transplant 21: 2696-2702.
7. Brukamp K, Jim B, Moeller MJ, Haase VH, (2007). Hypoxia and podocyte-specific Vhlh deletion confer risk of glomerular disease. Am J Physiol Renal Physiol 293: F1397-F1407.
8. Butts BD, Tran NL, Briehl MM, (2004). Identification of a functional peroxisome proliferator activated receptor response element in the 3′ untranslated region of the human bcl-2 gene. Int J Oncol 24: 1305-1310.
9. Chatterjee PK, (2007). Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 376: 1-43.
10. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, et al. (2005). The selective PPARγ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 68: 529-536.
11. Collino M, Patel NS, Thiemermann C, (2008). PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2: 179-197.
12. Conaldi PG, Biancone L, Bottelli A, De Martino A, Camussi G, Toniolo A, (1997). Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J Virol 71: 9180-9187.
13. Di Paola R, Cuzzocrea S, (2007). Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol 375: 157-175. (Pubitemid 46525445)
14. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, et al. (2001). Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephritic syndrome. Am J Pathol 158: 1723-1731.
15. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ, (2005). Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 288: F48-F57.
16. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, et al. (2003). Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425: 90-93.
17. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, et al. (2007). Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282: 37006-37015.
18. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. (2009). Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107.
19. Hondares E, Mora O, Yubero P, Rodriguez de la Concepción M, Iglesias R, Giralt M, et al. (2006). Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 147: 2829-2838.
20. Huber TB, Benzing T, (2005). The slit diaphragm: a signalling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14: 211-216.
21. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, et al. (2007). Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253: 53-60.
22. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, (2007). PPAR-γ agonist protects podocytes from injury. Kidney Int 71: 1232-1239.
23. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS, et al. (2003). Peroxisome proliferator-activated receptor-γ activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 307: 505-517.
24. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11.
25. Lambert R, Henry M, Howden B, Jablonski P, Rae D, Tavanlis G, et al. (1986). Glomerular damage after kidney preservation. Transplantation 42: 125-130.
26. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, et al. (2005). Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16: 2395-2402.
27. Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G, (2010). Stretch reduces nephrin expression via an Angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 298: F381-F390.
28. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R, (2009). PPARγ stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55: 496-504.
29. Miglio G, Varsaldi F, Francioli E, Battaglia A, Canonico PL, Lombardi G, (2004). Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. Eur J Pharmacol 489: 157-165.
30. Molitoris BA, Sutton TA, (2004). Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 66: 496-499.
31. Mukherjee R, Sun S, Santomenna L, Miao B, Walton H, Liao B, (2002). Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor. J Steroid Biochem Mol Biol 81: 217-225.
32. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR, (2003). The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333.
33. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR, (2004). Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78: 461-468.
34. Pippin J, Kumar V, Stein A, Jablonski P, Shankland SJ, Davis CL, (2009). The contribution of podocytes to chronic allograft nephropathy. Nephron Exp Nephrol 111: e1-e10.
35. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD, (2000). Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 278: F667-F675.
36. Ren S, Xin C, Beck KF, Saleem MA, Mathieson P, Pavenstädt H, et al. (2005). PPARα activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 338: 1818-1824.
37. Rippe C, Rippe A, Larsson A, Asgeirsson D, Rippe B, (2006). Nature of glomerular capillary permeability changes following acute renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 291: F1362-F1368.
38. Ruan X, Zheng F, Guan Y, (2008). PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 294: F1032-F1047.
39. Russ AL, Haberstroh KM, Rundell AE, (2007). Experimental strategies to improve in vitro models of renal ischemia. Exp Mol Pathol 83: 143-159.
40. Shankland SJ, (2006). The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147.
41. Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, et al. (2002). Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 8: BR532-BR539.
42. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, et al. (2003). Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23: 267-276.
43. Stefanidis I, Heintz B, Stöcker G, Mrowka C, Sieberth HG, Haubeck HD, (1996). Association between heparan sulfate proteoglycan excretion and proteinuria after renal transplantation. J Am Soc Nephrol 7: 2670-2676.
44. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, et al. (2003). Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
45. Tejada T, Catanuto P, Ijaz A, Santos JV, Xia X, Sanchez P, et al. (2008). Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 73: 1385-1393.
46. Villarroya F, Iglesias R, Giralt M, (2007). PPARs in the control of uncoupling proteins gene expression. PPAR Res 2007: 74364.
47. Wagner MC, Rhodes G, Wang E, Pruthi V, Arif E, Saleem MA, et al. (2008). Ischemic injury to kidney induces glomerular podocyte effacement and dissociation of slit diaphragm proteins Neph1 and ZO-1. J Biol Chem 283: 35579-35589.
48. Wiggins RC, (2007). The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71: 1205-1214.
49. Willson TM, Brown PJ, Sternbach DD, Henke BR, (2000). The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550.
50. Yang HC, Ma LJ, Ma J, Fogo AB, (2006). Peroxisome proliferator-activated receptor-γ agonist is protective in podocyte injury-associated sclerosis. Kidney Int 69: 1756-1764.
51. Zanetti M, Stocca A, Dapas B, Farra R, Uxa L, Bosutti A, et al. (2008). Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. J Mol Med 86: 185-195.